Undisclosed Cis-Targeted Programs

About Asher Biotherapeutics

Asher Bio is developing a new generation of immunotherapies using its proprietary cis-targeting platform, which aims to solve the fundamental challenge of selectivity by engaging both an immunomodulatory receptor and a specific surface marker on the same target cell. The company's lead program, etakafusp alfa, has demonstrated proof of mechanism and early anti-tumor activity in an ongoing Phase 1a/1b trial, validating the platform. With a pipeline extending into infectious diseases and a focus on strategic collaborations, Asher Bio is positioned to expand the therapeutic potential of immunomodulators across multiple indications.

Therapeutic Areas